Murchinson Criticizes the Nano Dimension Board of Directors’ Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics
Believes the Proposed Transaction Represents a Misallocation of Corporate Resources That Would Significantly Dilute Existing Shareholders
Finds It Deeply Concerning That This Morning's Conference Call Offered Shareholders Little Beyond Buzzwords and Provided No Opportunity to Ask Questions Regarding a Transaction That Materially Impacts the Future of the Company
Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 7.4% of the outstanding shares of Nano Dimension Ltd. (NASDAQ: NNDM) ("Nano" or the "Company"), today commented on Nano’s announcement that it has signed a non-binding term sheet with Infinite Epigenetics (“Infinite” or “Infinite Epigenetics”) to form a publicly traded, AI-powered health and diagnostics company.1
Among the most notable omissions from this morning’s conference call was any opportunity for Nano shareholders to ask questions regarding the proposed Infinite transaction. This Board of Directors (the “Board”), much like the previous Board under Yoav Stern, appears unwilling to answer necessary questions from shareholders about its decision-making. We therefore outlined below the questions we had intended to raise to CEO Dave Stehlin, in the interest of the transparency shareholders deserve.
